Additional file 1: Table S1. of Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer

Genomic positions and the primer sequences. (XLS 45 kb

Additional file 3: of Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy

Figure S1. Survival plot depicting the impact of Cyclin A1 expression (Affymetrix probe set 205899_at) on progression-free survival in the patient group with suboptimal debulking and platinum-based therapy using an online-accessible tool ( www.kmplot.com/ ), database version 2015 [n = 1648]. Case selection [n = 264]: survival: PFS, split patients by median; restrictions: FIGO II, III, IV; histology: serous; debulk: suboptimal; chemotherapy: contains platinum. Log-rank p = 0.0088. (PPTX 84 kb

Additional file 1: Table S1. of Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Treatment costs according to type of first-line treatment received by patients with EGFR Mut + NSCLC. (DOCX 15 kb

ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression-1

Apillary () and chromophobe () renal cell carcinoma with strong ADAM9 expression. Normal renal tissue with weak () and strong () ADAM9 expression.<p><b>Copyright information:</b></p><p>Taken from "ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression"</p><p>http://www.biomedcentral.com/1471-2407/8/179</p><p>BMC Cancer 2008;8():179-179.</p><p>Published online 26 Jun 2008</p><p>PMCID:PMC2442841.</p><p></p

ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression-3

S was normalized to the geometric mean of the two reference genes PPIA and TBP. For most cases mRNA levels of the renal cell cancers laid above those of the normal tissue standard.<p><b>Copyright information:</b></p><p>Taken from "ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression"</p><p>http://www.biomedcentral.com/1471-2407/8/179</p><p>BMC Cancer 2008;8():179-179.</p><p>Published online 26 Jun 2008</p><p>PMCID:PMC2442841.</p><p></p

ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression-2

Old line) revealed significantly shortened patient survival times if compared to those with low ADAM9 expression (dotted line).<p><b>Copyright information:</b></p><p>Taken from "ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression"</p><p>http://www.biomedcentral.com/1471-2407/8/179</p><p>BMC Cancer 2008;8():179-179.</p><p>Published online 26 Jun 2008</p><p>PMCID:PMC2442841.</p><p></p

ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression-0

S was normalized to the geometric mean of the two reference genes PPIA and TBP. For most cases mRNA levels of the renal cell cancers laid above those of the normal tissue standard.<p><b>Copyright information:</b></p><p>Taken from "ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression"</p><p>http://www.biomedcentral.com/1471-2407/8/179</p><p>BMC Cancer 2008;8():179-179.</p><p>Published online 26 Jun 2008</p><p>PMCID:PMC2442841.</p><p></p

Criteria for evaluating discrepancies modified after Goldman et al. (1983) and Battle et al. (1987).

<p>Criteria for evaluating discrepancies modified after Goldman et al. (1983) and Battle et al. (1987).</p

Clinical information and meta data about autopsy patients from 1988 to 2008.

<p>The data presented here do not reveal significant differences between “all” and “study” group concerning the distribution of the characteristics considered, therefore representativeness can be assumed.</p

Development of the discrepancies between clinical and pathological diagnoses at the Charité hospital during the last 20 years.

<p>300 cases were included into the analysis for each of the years 1988 (GDR), 1988 (FRG), 1993, 1998, 2003 and 2008. Cases were assigned to discrepancy classes I to VI according to the modified Goldman criteria. a) Country and time dependent distribution of the discrepancy classes I–VI. b) Significant decrease of major discrepancies and significant increase of minor discrepancies between 1988 and 2008. 1988 =  pooled GDR and FRG cases.</p